Physician profile
James Tierney
NPI 1205920261
$5,826.80
in general payments reported to CMS, 2019-2025
23 companies · $479 in 2025
The $479 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,086 · 2020: $204 · 2021: $388 · 2022: $424 · 2023: $641 · 2024: $2,605 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,178 · Travel and Lodging: $1,433 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,178.27 |
| Travel and Lodging | $1,432.74 |
| Education | $114.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $2,578.51 | 2023-2024 | Axonics, Bulkamid |
| Myriad Genetic Laboratories, INC. | $533.99 | 2021-2025 | Prolaris |
| Boston Scientific Corporation | $441.73 | 2019-2021 | |
| Medtronic USA, INC. | $347.07 | 2019-2020 | |
| Intuitive Surgical, INC. | $337.59 | 2019-2021 | |
| Pfizer INC. | $234.92 | 2019-2025 | |
| Medtronic, INC. | $224.18 | 2021-2023 | Interstim |
| Janssen Scientific Affairs, LLC | $150.00 | 2025 | |
| Endo Pharmaceuticals INC. | $128.72 | 2019 | |
| Urogen Pharma, INC. | $125.00 | 2022 | |
| Astellas Pharma US INC | $107.22 | 2023-2025 | Xtandi |
| Karl Storz Endoscopy-America | $103.54 | 2021 | |
| Abbvie INC. | $98.24 | 2024-2025 | |
| Ethicon INC. | $86.23 | 2019 | |
| Seagen INC. | $78.99 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $66.39 | 2023 | |
| Sumitomo Pharma America, INC. | $42.94 | 2023 | Gemtesa |
| Ambu INC. | $39.92 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Coloplast Corp | $30.39 | 2025 | |
| Urovant Sciences INC | $21.05 | 2022 | |
| Ferring Pharmaceuticals INC. | $15.12 | 2024 | Adstiladrin |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$408.78 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Tierney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.